remain one favorit name coverag follow recent launch
manag care reevalu model increment posit
believ bring differenti integr model share still extrem
under-valued see upsid estim
mani view retail pharmaci liabil believ view
asset help drive growth build clinic strategi particularli use
telemedicin note recent studi jama highlight better outcom manag
chronic condit like hypertens telemedicin care deliv
pharmacist nurs practition fit well clinic model believ use
technolog like also reinforc physic clinic provid low- high-
touch model care could effect manag fragil patient popul
despit roughli move share sinc start august still trade
pro-forma adj ep estim compar manag care
average trade estim similar view ci/esrx
believ valu sum greater part evidenc market
view note revis pt impli share trade
estim roughli in-line target multipl ci/esrx appli
multipl would impli pt indic futur upsid opportun
note current guidanc doesnt includ revenu synergi
believ even cost/sav side like see upsid estim
signific portion strategi focus aet senior membership aet
like oper near high-end target margin rang see least two potenti
increment driver growth profit abil increas touchpoint
member pharmaci could allow aet improv patient risk score
receiv higher risk-adjust payment opportun convert portion
pdp membership higher pmpm higher margin busi abl
convert pdp member member estim would contribut
adj ep estim
lower adj ep estim larg due lower synergi
assumpt maintain adj ep estim lower contribut
off-set greater synergi year two acquisit rais pt
base revis dcf analysi indic share
trade adj ep estim
pleas see page report import disclosur
current invest thesi lie acquisit aet view favor
think care coordin combin entiti posit well value-bas
care believ differenti model like lead best outcom lower cost
manag chronic condit use minuteclin leverag telemedicin non-
physician provid addit share look under-valued current level pro forma
basi rel peer pharma suppli chain manag care
 progress regulatori approv
process pend acquisit aet
 top-lin growth retail/ltc
revenu pbm revenu
 oper margin modestli
y/i due increment oper expens
reinvest mix shift toward
pbm segment
 assum share repo
 strong retail comp better macro
environ coupl better pbm
 stronger gener lower
 sooner expect close aet
 slower expect growth
 weaker expect gener
greater expect reimburs
one largest drug retail chain compani larg oper
two main busi segment pharmaci servic retail pharmaci
retail pharmaci segment compani oper drugstor on-line retail
pharmaci websit well health clinic store sell prescript drug
wide array gener merchandis refer front end product
compani also provid full rang pbm servic client mainli includ
organ sponsor health benefit plan servic includ formulari
servic diseas manag program pharmacogenom servic
reiter outperform rate remain one favorit name
coverag follow recent launch manag care reevalu
model increment posit believ current valuat
consider underappreci strateg valu uniqu suit asset
includ legaci retail pharmaci pharmaci benefit busi along
insur busi current process acquir via aet unlik
integr model advantag frequent conveni interact
patient retail pharmaci locat well minuteclin focu
coordin care chang patient behavior better manag chronic condit
elimin wast healthcar spend could result greater margin
enterpris well competit price patient manag believ
could result share gain time sum-of-the-part analysi base discount
valuat assumpt rel unh insur pbm busi yield price
target impli upsid current level also see upsid
estim revenu synergi greater expect cost synergi lastli
pro-forma basi current trade discount manag care
peer pharma suppli chain peer well regulatori approv
close transact expect multipl expand time
cvs/aet chart slightli differ path pbm-insur combin seek
leverag retail footprint drive greater front-end sale expand
number servic perform minuteclin increas number touchpoint
health plan member compani emphas doesnt intend replac
primari care rather supplement primari care physician
current bandwidth monitor interven necessari visit
could potenti see certain instanc could look partner
healthcar provid provid wrap-around type servic compani focu
chronic care manag rather acut care servic urgent care clinic
provid distinct path take co-loc medexpress urgent
care center certain locat focu chronic care expect less capital-
intens focus hub-and-spok model subset store
closest largest number member enhanc minuteclin
servic along leverag telemedicin note recent studi journal
american medic associ demonstr better outcom use
telemedicin chronic condit hypertens along intervent
non-physician provid nurs practition view posit sign
path open prior aet deal compani note
econom attract sinc benefit chronic care manag
accru payor acquir aet chang dynam make busi
case viabl believ better care coordin minuteclin
could result lower overal cost trend health plan could allow
compani improv margin gain market share acquisit aet
abl retain cost save within enterpris howev unclear much
save term dollar lower medic cost trend minuteclin
technolog asset could gener make difficult quantifi potenti
given focu chronic care manag believ signific portion
strategi center around aet senior membership like less opportun
improv margin book busi particularli medicar advantag
believ aet oper near high-end target margin rang see
least two potenti benefit strategi first abil increas touchpoint
member could allow aet improv patient risk score potenti result
accur code member condit higher risk-adjust payment
health plan second see opportun convert portion medicar part
membership medicar advantag higher pmpm higher margin busi
abl convert medicar part member medicar advantag
member estim would worth increment adj ep
estim figur expect like increas in-stor market effort
order tri convert medicar part member medicar advantag member
aet well posit grow medicar advantag busi stand-alon basi
next year strong growth year compani expect exceed
industri averag growth rate medicar advantag next year particularli
individu medicar advantag drive growth medicar advantag key aet
believ compani oper near high-end target margin rang
believ potenti divestitur aet million medicar part live
materi impact compani strategi assum pre-tax margin
share count million estim medicar part worth ep
aet repres littl ep estim
figur potenti revenu synergi convert medicar part
member medicar advantag
million except per-shar data
cowen compani
base assum valuat unh busi segment perform sum-of-
part analysi impli price target figur assign
ev/ebitda multipl unh insur busi unh hcit
busi optuminsight unh provid busi optumhealth
base unh current share price impli valuat unh pbm
optumrx note may question multipl select
variou segment realiti conserv
assumpt segment impli valuat pbm would
even higher use valuat multipl refer appli ev/ebitda
multipl cvs/aet three busi segment assum ev/ebitda multipl
cvs/aet insur busi three turn unh multipl
given attract mix busi higher also assum
ev/ebitda multipl pbm caremark discount unh
pbm believ optumrx current valuabl caremark given
unh medic pharmaci data integr cvs/aet first
year merger lastli assum conserv multipl retail
pharmaci busi result valuat assumpt estim
sum-of-the-part analysi yield price target believ time
may abl achiev insur pbm segment valuat closer
think cvs/aet pbm multipl in-lin unh pbm multipl expect
insur busi alway valu discount unh insur busi
due less attract busi mix note appli unh insur
pbm multipl cvs/aet would impli price target
million except per-shar data
cowen compani
believ share look compel current level trade
pro-forma adj ep estim figur discount manag
care peer particularli glare manag care name trade averag
adj ep trade discount manag care peer
trade discount pharma suppli chain peer well pharma
suppli chain trade averag valuat dispar valuat
multipl rel peer even greater achiev synergi higher
million manag expect think like well realiz
revenu synergi arent includ financi model fact note
manag meet long-term opportun exist bend cost
curv wont identifi quantifi close merger given
limit access aet data current said approv close
transact think dispar peer pharma
suppli manag care diminish impli substanti upsid current
level base updat price target expect upsid
impli price-to-earn ratio think rel conserv
given in-lin current pharma suppli chain valuat well
figur vs pharma suppli manag compar trade multipl
amount millsion expect per share data
thomson eikon cowen compani
think high level free cash flow gener result merger aet
overlook particularli outer year provid
consider financi flexibl base updat pro-forma model estim
free cash flow almost billion first year acquisit grow
billion figur note free cash flow could even greater
revenu synergi realiz synergi manag expect due
high level free cash flow achiev leverag ratio well
manag target leverag ratio low addit free cash
flow yield larg in-lin pharma suppli chain averag
free cash flow yield well pharma suppli chain averag
figur
billion
cowen compani
figur free yield vs pharma suppli chain manag peer
amount millsion expect per share data
cowen compani
remain confid abl gain regulatori approv
depart justic doj merger aet particularli light approv
merger ci esrx recent announc divestitur aet
medicar part busi wcg also appear make progress
gain approv state insur board alreadi receiv
approv state
base confer call anti-trust expert think horizont
overal medicar part like concern doj approv
cvs/aet merger announc aet agre divest medicar part
busi wcg per aet file septemb think
likelihood gain approv increas make manag time-frame close
transact earli achiev may concern regard
doj accept divestitur suitabl remedi believ doj
like view propos remedi favor aet divest entir part book
rather portion wcg like view suitabl buyer
busi given sizabl exist part membership believ wcg abl
take addit pdp live modest increment invest spend
aet provid administr servic retain financi risk busi
throughout repres potenti red flag believ
prevent deal go given bid alreadi submit
aet brand market activ open enrol schedul
begin octob believ administr servic agreement put place
minim potenti disrupt member rather suggest wcg need time
build infrastructur order take busi note wcg
fourth largest market share pdp among publicli trade health plan
approxim septemb acquisit place wcg third
largest pdp plan term market share behind market
share market share
continu make progress gain state approv merger
continu make progress gain approv state insur board
alreadi receiv approv state leav state approv
outstand figur arent overli concern outstand approv
given manag previou comment state insur board run
parallel process doj expect receiv approv state
insur board soon doj addit express concern
certain state new york california may move block merger
base convers aet think larg unfound concern
accord aet insur commission make statement
competit market isnt len suppos
review transact doj entiti suppos evalu
impact competit state insur commission suppos evalu
suitabl new ownership regard california aet note law could
give agenc leverag secur commit compani
unclear whether legal author forc compani come
figur state approv receiv outstand
cowen compani
potenti loss safe harbor protect drug rebat longer signific
concern share along rest pharma suppli chain
pressur trump administr work propos lower drug
price first trump releas american patient first mid-may follow
propos regul entitl remov harbor protect rebat plan
pbm involv prescript creation new harbor
protect sent offic manag budget omb mid-juli
howev overhang relat loss rebat new drug price mechan
implement larg remov sinc manag commentari last
earn call return custom rebat retain
million rebat annual adj ep
even new drug price mechan put place dont think rebat go away
rather think rebat replac up-front discount magnitud
still depend scale posit formulari believ
case today rebat system remnant previou era
consolid pbm space market share evenli spread across
numer pbm retroact discount form rebat provid
manufactur mean compens pbm adequ move share
howev market share concentr larg among three larg player
compris caremark esrx optumrx
demonstr abil shift market share formulari manag think
up-front discount commensur scale make sens addit
demonstr abil move share incent rebat larg thing
past simpler gener rebat format common anyway see
reason manufactur comfort model well
furthermor elimin rebat would challeng given theyr current fulli
integr three core book busi compris medicar
medicaid commerci elimin rebat would implic
medicaid particularli regard medicaid best price rule implic
state budget reli drug rebat medicaid drug rebat
program manufactur requir provid state rebat due
medicaid best price rule state also receiv supplement rebat manufactur
commerci rebat exceed importantli rebat written statut
would need act congress chang think challeng
would suggest administr would limit rule chang
perhap explain titl recent propos omb elimin
safe harbor provis also creation new safe harbor provis
addit elimin rebat commerci market would like impact
budget premium entiti purchas drug discount would
impact well va feder suppli schedul program
particip program would also impact elimin
rebat buy drug discount price includ rebat
sell list price margin list net design compens
provid free discount care provid uninsur
updat estim price target refin assumpt notabl
intric manag care segment build follow recent manag care
launch result lower adj ep estim larg
due lower synergi assumpt first year aet acquisit
maintain adj ep estim lower contribut
off-set greater synergi year two acquisit rais price target
base revis five-year dcf analysi indic share
trade adj ep estim
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang net work terminal- valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per-shar data
compani report cowen compani
interseg net good interseg net cost good gross gross chang oper oper chang intang interest expens expenses- pre-tax pre-tax chang adj incom tax provis effect tax net adj net incom chang earn alloc particip net incom attribut non-controlling adj net incom attribut intang loss earli extinguish debt- loss discontinu operations- net loss non-controlling acquisition-rel financ non-recur net weight averag dilut share adj ebitda chang chang y/i net net incom attribut end decemb cowen
million except per-shar data
compani report cowen compani
interseg net good interseg net cost good gross gross chang oper oper chang intang interest expens pre-tax pre-tax chang adj incom tax provis effect tax net adj net incom chang earn alloc particip net incom attribut non-controlling adj net incom attribut intang loss earli extinguish debt- loss discontinu operations- net loss non-controlling acquisition-rel financ non-recur net weight averag dilut share adj ebitda chang chang y/i net net incom attribut cowen
million
compani report cowen compani
cash short-term account receiv defer incom current current properti equip intang asset total liabil account claim discount accru short-term debt- current portion long-term current long-term defer incom non-curr redeem non-controlling stockhold equiti common treasuri share held capit retain accumul comprehens total health sharehold non-controlling total sharehold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti decemb cowen
million
compani report cowen compani
income/ loss adjust requir reconcil net incom net cash provid oper activ depreci goodwil loss settlement defin benefit pension stock-bas defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv current account payabl claim discount accru long-term net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur exclud non-recur itemsyear end decemb cowen
million
compani report cowen compani
activitiesnet adjust requir reconcil net incom net cash provid oper activ depreci goodwil impairments- loss settlement defin benefit pension plans- stock-bas loss earli extinguish defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv current account payabl claim discount accru long-term net cash provid oper invest activitiespurchas properti proce sale-lease-back proce sale properti equip acquisit net cash acquir purchas available-for-sal sale matur available-for-sal net cash use invest financ activitiesincreas decreas short-term proce issuanc long-term repay long-term purchas non-controlling interest subsidiary- payment conting consideration- dividend proce exercis stock payment tax relat net share settlement equiti repurchas common other- net cash provid use financ effect exchang rate net decreas cash cash cash equival begin cash equival end year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
lack regulatori approv acquisit aet challeng
slower expect onboard contract
